Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.32 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15184583 | 0.84 | AAK1 (0.51) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL14088011 | 0.84 | PRMT5 (0.50) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL16316699 | 0.82 | PRMT5 (0.44) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL15261649 | 0.81 | PRMT5 (0.56) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL4931587 | 0.80 | AAK1 (0.40) | AAK1BACE1CYP17A1 | |
| SCHEMBL1646602 | 0.80 | AAK1 (0.52) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL65546 | 0.78 | AAK1 (0.53) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL30931999 | 0.78 | AAK1 (0.50) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL4822133 | 0.77 | AAK1 (0.59) | PRMT5WDR77AAK1HIF1ADGAT1 | |
| SCHEMBL65795 | 0.77 | AAK1 (0.49) | PRMT5WDR77AAK1HIF1ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2008-08-14 | — | — | US | disclosed |
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | MAOA, MAOB, COMT | PRMT5 1979/4885WDR77 3167/4885AAK1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.